Abstract
H1 Patent – European patent – Combination drug for treatment of breast-cancer – Action for revocation – Purpose-limited process claims – Purpose-limited product claims – Construction – ‘For’ claims – Skilled person – Common general knowledge – Lack of novelty – Anticipation – Disclosure of existence of clinical trials – Whether claimed clinical benefit directly and unambiguously disclosed – Inevitable result – Mental element in claim – Obviousness – Fair expectation of success – Skilled person’s assessment of prior art
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
